Remove Doctors Remove Food and Drug Administration Remove Healthcare Remove Medicine
article thumbnail

Disruption in healthcare is coming

World of DTC Marketing

America’s profit-riddled healthcare-industrial complex consumes 17% of GDP, equivalent to $3.6trn a year. However, changes are slowly being implemented that could lower healthcare costs. Healthcare is ripe for disruption, but any attempt to disrupt our state of healthcare has been met with pushback and challenges.

article thumbnail

What do future healthcare CEOs look like?

World of DTC Marketing

American healthcare is in trouble. I have to laugh when I hear that a pharma company is patient-centric because that’s become a slogan to make employees feel good about themselves while the costs of prescription drugs increase every year. Highest-paid CEOs in 2019: Who made the list from healthcare. This has to end.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Psychedelic medicines: are they gaining traction in Europe?

European Pharmaceutical Review

As psychedelics diffused into wider society and recreational use increased, some individuals reported…ongoing symptoms after the drugs had left the body” At a time when psychiatry lacked effective medical therapies, the discovery of LSD was of interest.

Medicine 113
article thumbnail

Securing every dose with an edible security technology for safe medicines

European Pharmaceutical Review

FAKE MEDICINES are not a new problem, and pose a tremendous threat to patient safety and public health in society regardless of a country’s economic status. The prevalence of fake drugs is a continually growing problem worldwide. Some, 250,000 child deaths per year can be attributed to counterfeit malaria and pneumonia medicines.

article thumbnail

Delivery systems for biologics

European Pharmaceutical Review

As a cornerstone of advanced therapeutics in modern medicine, biologics command significant attention in the search for effective treatments for human diseases. 1 However, the entry of biologics into the pharmaceutical market is not without unique challenges, particularly when compared to small molecule drugs. percent through 2027.

article thumbnail

First biosimilar to HUMIRA® available in US

European Pharmaceutical Review

Amgen’s AMJEVITA was the first biosimilar to Humira approved by the US Food and Drug Administration (FDA), in 2016. “AMJEVITA provides another treatment option for patients and their doctors.” Amgen currently has 11 biosimilar medicines in market or under development.

article thumbnail

Antibody drug conjugates and bispecifics seize the spotlight at ASCO 2022

Clarivate

As part of our Drugs to Watch series, our team of oncology experts pored over thousands of abstracts for presentations at this year’s just-concluded American Society of Clinical Oncology (ASCO) Annual Meeting. This signifies the growth potential of marketed drugs in established marketplaces and the complexity of oncology treatment paradigms.